Antibody methods for selectively inhibiting VEGF

Details Antibody methods for selectively inhibiting VEGF Antibody methods for selectively inhibiting VEGF

2006-06-06

2006-06-06

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S184100, C530S387100, C530S388100, C530S388150, C530S388250, C530S809000, C530S864000, C530S865000, C530S866000

Reexamination Certificate

active

07056509

ABSTRACT:
Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

REFERENCES:
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 4925922 (1990-05-01), Byers et al.
patent: 4940726 (1990-07-01), Pettit et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5008196 (1991-04-01), Connolly et al.
patent: 5036003 (1991-07-01), Olander et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5354778 (1994-10-01), Ray et al.
patent: 5561122 (1996-10-01), Pettit
patent: 5569786 (1996-10-01), Pettit et al.
patent: 5587297 (1996-12-01), Jacobson et al.
patent: 5659013 (1997-08-01), Senger et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5677181 (1997-10-01), Parish
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5730977 (1998-03-01), Ooka et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5786344 (1998-07-01), Ratain et al.
patent: 5840301 (1998-11-01), Rockwell et al.
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 5866127 (1999-02-01), Senger et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5874081 (1999-02-01), Parish
patent: 5874542 (1999-02-01), Rockwell et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5942385 (1999-08-01), Hirth
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 6004554 (1999-12-01), Thorpe et al.
patent: 6004555 (1999-12-01), Thorpe et al.
patent: 6007817 (1999-12-01), Epstein et al.
patent: 6008319 (1999-12-01), Epstein et al.
patent: 6020473 (2000-02-01), Keyt et al.
patent: 6022541 (2000-02-01), Senger et al.
patent: 6024955 (2000-02-01), Asano et al.
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6121230 (2000-09-01), Charnock-Jones et al.
patent: 6291667 (2001-09-01), Gill et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6416758 (2002-07-01), Thorpe et al.
patent: 6524583 (2003-02-01), Thorpe et al.
patent: 6582959 (2003-06-01), Kim
patent: 6676941 (2004-01-01), Thorpe et al.
patent: 6703020 (2004-03-01), Thorpe et al.
patent: 2002/0032315 (2002-03-01), Baca et al.
patent: 2002/0098187 (2002-07-01), Ferrara et al.
patent: 2003/0086919 (2003-05-01), Rosenblum et al.
patent: 2003/0190317 (2003-10-01), Baca et al.
patent: 2003/0203409 (2003-10-01), Kim
patent: 2003/0206899 (2003-11-01), Ferrara et al.
patent: 0 484 401 (1996-09-01), None
patent: 0 666 868 (2002-04-01), None
patent: WO 90/13649 (1990-11-01), None
patent: WO 91/02058 (1991-02-01), None
patent: WO 92/14748 (1992-09-01), None
patent: WO 93/08210 (1993-04-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/11499 (1994-05-01), None
patent: WO 95/21868 (1995-08-01), None
patent: WO 96/01653 (1996-01-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/45332 (1998-10-01), None
patent: WO99/40118 (1999-08-01), None
patent: WO 00/34337 (2000-06-01), None
patent: WO 00/37502 (2000-06-01), None
patent: WO 01/54723 (2001-08-01), None
Storkebaum et al., “VEGF: Once Regarded as a Specific Angiogenic Factor, Now Implicated in Neuroprotection,”BioEssays,26:943-954, 2004.
Fishman et al., “Autoimmunity and Cancer—Beneficial Relationships: A New Concept for the Production of Human Monoclonal Antibodies (Review),”Int. J. Oncol.,10:901-904, 1997.
Tschmelitsch et al., “Enhanced Antitumor Activity of Combination Radioimmunotherapy (1311-Labeled Monoclonal Antibody A33) with chemotherapy (Fluorouracil),”Cancer Res.,57:3181-3186, 1197.
Ben-Hur and Orenstein, “The Endothelium and Red Blood Cell as Potential Targets in PDT-Induced Vascular Stasis,”J. Radiat. Biol.,60(1/2):293-301, 1991.
Folkman, “Tumor Angiogenesis,”Adv. Cancer Res.,43:175-203, 1985.
Gschwind et al., “The Discovery of Receptor Tyrosine Kinases: Targets for Cancer Therapy,”Nature Reviews/Cancer,4:361-370, 2004.
Martiny-Baron and Marmé´, “VEGF-Mediated Tumour Angiogenesis: A New Target for Cancer Therapy,”Curr. Opin. Biotech.,6:675-680, 1995.
McDonald and Baluk, “Significance of Blood Vessel Leakiness in Cancer,”Cancer Research,62:5381-5385, 2002.
Murata et al., “Immunohistochemical Detection of Extravasated Fibrinogen (Fibrin) in Human Diabetic Retina,”Graefe's Arch. Clin. Exp. Opthalmol.,230:428-431, 1992.
Risau, “What, if anything, is an Angiogenic Factor?”Cancer Metastasis Rev.,15:149-151, 1996.
Senger et al., “Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid,”Science,219:983-985, 1983.
Sioussat et al., “Inhibition of Vascular Permeability Factor (Vascular Endothelial Growth Factor) with Antipeptide Antibodies,”Arch. Biochem. Biophys.,301(1):15-20, 1993.
Wiig et al., “Interstitial Fluid Pressure in DMBA-Induced Rat Mammary Tumours,”Scand. J. Clin. Lab. Invest.,42:159-164, 1982.
Stephan et al., “Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer,”Clin. Can. Res.,10:6993-7000, 2004.
Aiello, “Suppression of Retinal Neovascularization In Vivo by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins,”Proc. Natl. Acad. USA,92:10457-10461, 1995.
Broadley et al., “Monospecific Antibodies Implicate Basic Fibroblast Growth Factor in Normal Wound Repair,”Lab. Invest.,61(5):571-575, 1989.
Brock et al., “Tumor-Secreted Vascular Permeability Factor Increases Cytosolic Ca2+and von Willebrand Factor Release in Human Endothelial Cells,”Am. J. Path.,138(1):213-221, 1991.
Brown et al., “Leaky Vessels, Fibrin Deposition, and Fibrosis: A Sequence of Events Common to Solid Tumors and to Many Types of Disease,”Am. Rev. Respir. Dis.,140:1104-1107, 1989.
Clauss et al., “Vascular Permeability Factor: A Tumor-Derived Polypeptide that Induces Endothelial Cell and Monocyte Procoagulant Activity, and Promotes Monocyte Migration,”J. Exp. Med.,172:1535-1545, 1990.
Conn et al., “Purification of a Glycoprotein Vascular Endothelial Cell Mitogen from a Rat Glioma-Derived Cell Line,”Proc. Nat. Acad. Sci. USA,87:1323-1327, 1990.
Conn et al., “Amino Acid and cDNA Sequences of a Vascular Endothelial Cell Mitogen that is Homologous to Platelet-Derived Growth Factor,”Proc. Natl. Acad. Sci. USA,87:2628-2632, 1990.
Connolly, “Vascular Permeability Factor: A Unique Regulator of Blood Vessel Function,”J. Cell Biochem.,47:219-223, 1991.
Connolly, “Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis,”J. Clin. Invest.,84:1470-1478, 1989.
Denekamp, “Vasculature as a Target for Tumour Therapy,”Prog. Appl. Microcirc.,4:28-38, 1984.
Dennis and Rifkin, “Studies on the Role of Basic Fibroblast Growth FactorIn Vivo: Inability of Neutralizing Antibodies to Block Tumor Growth,”J. Cell. Physiol.,144:84-98, 1990.
Dvorak et al., “Vascular Permeability Factor, Fibrin, and the Pathogenesis of Tumor Stroma Formation,”Ann. N.Y. Acad. Sci.,667:101-111, 1992.
Dvorak, “Leaky Tumor Vesssels: Consequences for Tumor Stroma Generation and for Solid Tumor Therapy,”Progress in Clinical and Bioilogical Research,354a: 317-330, 1990.
Dvorak, “Tumors: Wounds That Do Not Heal,”New Eng. J. Med.,315(26):1650-1659, 1986.
Dvorak et al., ȁ

Affiliated with

Also associated with

Rating

Antibody methods for selectively inhibiting VEGF does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody methods for selectively inhibiting VEGF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody methods for selectively inhibiting VEGF will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3706235